Synact Pharma is working on the development of new drugs to treat inflammatory disorders such as rheumatoid arthritis.

The company was founded in 2012 by Professor Søren Nielsen and Research Director Thomas Jonassen with CAPNOVA as an investor.

In July 2016, Synact Pharma joined the stock exchange Spotlight Stock Market in Sweden, raising SEK 12.5 million. It was at this time that CAPNOVA exited the company.

In 2017, the company initiated a phase-1 clinical trial of their drug candidate AP1189, which is targeted for the treatment of arthritis, including psoriasis arthritis, an acute form of arthritis affecting approx. 30% of all patients with psoriasis. The drug candidate has shown promising results in preclinical studies, where there have been indications that the drug can be used for other chronic inflammatory diseases (Synactpharma.com).